General Information of the Drug (ID: M6APDG02986)
Name
Abaloparatide
Synonyms
Tymlos
    Click to Show/Hide
Status
Approved
Structure
3D MOL
PubChem CID
76943386
TTD Drug ID
D02CII
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Parathyroid hormone 1 receptor (PTH1R)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Parathyroid hormone 1 receptor (PTH1R) is a therapeutic target for Abaloparatide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Abaloparatide through regulating the expression of Parathyroid hormone 1 receptor (PTH1R). [1], [2]
References
Ref 1 Mettl3-mediated m(6)A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat Commun. 2018 Nov 14;9(1):4772. doi: 10.1038/s41467-018-06898-4.
Ref 2 US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.